Michael Brundage
机构: Professor of Oncology and Public Health Sciences, Queen's University
每年引用次数
引用次数
引用: 18,871
H-指数: 69
I10-指数 : 204
出版物: 493
Peer-review of radiation treatment planning in a provincial radiation oncology program: A survey of current practice.
Thomas S. McGowan , Sophie Foxcroft , Michael Donald Brundage , Michael Sharpe
Journal of Clinical Oncology 30 211 -211
2012
The Canadian partnership for quality radiotherapy: A model for radiation treatment quality and safety.
Jeffrey Quoc Cao , Jean-Pierre Bissonnette , Michael Donald Brundage , Peter Dunscombe
Journal of Clinical Oncology 30 266 -266
1
2012
Creation of On-PROST: The Ontario patient-reported outcomes of symptoms and toxicity applied clinical research unit.
Geoffrey Liu , Doris Howell , Andrea Perez Cosio , Monika K Krzyzanowska
Journal of Clinical Oncology 30 47 -47
2012
Association between progression-free survival and health-related quality of life in oncology: A systematic review and regression analysis.
Bruno Kovic , Xuejing Jin , Lehana Thabane , Gordon Guyatt
Journal of Clinical Oncology 35 6574 -6574
2017
Evaluation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) tool: Acceptability, feasibility and potential role in enhancing clinical care of men with early-stage prostate cancer.
Doris Howell , Sarah Stevens , Farzana Haji , Zahra Ismail
Journal of Clinical Oncology 34
2016
An approach to implementing meaningful change in a provincial health care system.
Michelle Ang , Elizabeth Lockhart , Michael Donald Brundage , Margaret Hart
Journal of Clinical Oncology 34 ( 7_suppl) 120 -120
2016
Toward quality peer review: Outcomes of peer review across provincial radiation oncology programs.
Julie Rouette , Jennifer O'Donnell , Sophie Foxcroft , Margaret Hart
Journal of Clinical Oncology 34 ( 7_suppl) 205 -205
2016
“It looks good”: How a provincial radiation oncology program benefits from implementing peer review across cancer centers.
Michael Donald Brundage , Margaret Hart , Jennifer O'Donnell , Sophie Foxcroft
Journal of Clinical Oncology 34 ( 7_suppl) 238 -238
2016
Quality of radiation therapy referral and utilization post-prostatectomy: A population-based study of time trends.
Chunzi Jenny Jin , Michael Donald Brundage , Earl Francis Cook , Qun Miao
Journal of Clinical Oncology 34 ( 7_suppl) 286 -286
1
2016
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Julie Lemieux , Paul E. Goss , Wendy R. Parulekar , James N. Ingle
Journal of Clinical Oncology 34 ( 18_suppl) LBA506 -LBA506
5
2016
The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.
Harry Brastianos , Jure Murgic , Adriana Salcedo , Melvin Lee Kiang Chua
Journal of Clinical Oncology 37 46 -46
1
2019
Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).
Di Maria Jiang , Michael Donald Brundage , Christopher Sweeney , Karim Fizazi
Journal of Clinical Oncology 37 478 -478
1
2019
Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110).
Malcolm David Mason , Wendy Parulekar , Matthew Robert Sydes , Mahesh Parmar
Journal of Clinical Oncology 30 4509 -4509
6
2012
Evaluation of the implementation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) across the province of Ontario.
Farzana Haji , Lisa Catherine Barbera , Heidi Amernic , Jenna Evans
Journal of Clinical Oncology 36 188 -188
2018
Defining a patient-reported outcome measure (PROM) selection process: What criteria should be considered when choosing a PROM for routine symptom assessment in clinical practice?
Nicole Montgomery , Susan J Bartlett , Michael Donald Brundage , Denise Bryant-Lukosius
Journal of Clinical Oncology 36 187 -187
1
2018
Cancer survival outcomes in Ontario, Canada: Significant unexplained variation.
Michael Donald Brundage , Patti Groome , Timothy Hanna , Christopher M. Booth
Journal of Clinical Oncology 36 36 -36
3
2018
Imaging progression-free survival: How much does it matter to patients?
Jennifer O'Donnell , Andrew George Robinson , Christopher M. Booth , Rachel Koven
Journal of Clinical Oncology 36 99 -99
2
2018
CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).
Wassim Kassouf , Simon J Crabb , Ignacio Duran , Michael Donald Brundage
Journal of Clinical Oncology 40 ( 16_suppl) TPS4619 -TPS4619
4
2022
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO. 21).
Christopher M Booth , Janette L Vardy , Christopher J O'Callaghan , Sharlene Gill
Journal of Clinical Oncology 33 ( 15_suppl) TPS3620 -TPS3620
2015